Potentia presents early data from Ph I AMD trial

Potentia Pharmaceuticals, a privately-held US biotechnology company developing medicines for the treatment of age-related macular degeneration, presented Phase I data from the ASaP trial of its lead candidate, POT-4, at the American Academy of Ophthalmology meeting in Atlanta.

Interim results of the first-in-man, multicenter, single escalating dose study revealed no drug-related, toxicity-based on clinical signs, ophthalmic examinations or laboratory results at any point in patients treated with up to 150mcg of POT- 4. Additionally, no serious adverse events and no identifiable intraocular inflammation were reported.

"These safety data strongly support the further development of POT-4 as a potential treatment for patients with AMD," said chief executive Cedric Francois. "We believe that the product has significant promise, based on these early-stage findings, and look forward to further testing of the compound in higher doses as we continue this trial," he added.